Brolucizumab is a humanized monoclonal antibody belonging to the anti-VEGF class, designed to treat neovascular or wet age-related macular degeneration by inhibiting vascular endothelial growth factor… Read more
Brolucizumab is a humanized monoclonal antibody belonging to the anti-VEGF class, designed to treat neovascular or wet age-related macular degeneration by inhibiting vascular endothelial growth factor A to reduce abnormal retinal blood vessel growth. The available Brolucizumab reference standards and related impurities are essential tools for pharmaceutical laboratories engaged in rigorous quality control and impurity profiling. Chemists utilize these high-quality materials to establish reliable analytical methods, ensuring the drug’s stability and potency throughout its lifecycle. Additionally, stable isotope-labelled compounds within this category serve as critical internal standards for accurate quantification and method validation during complex bioanalytical studies. By providing precise reference points for identifying degradation products and process-related impurities, these compounds facilitate adherence to stringent regulatory standards required for ensuring the efficacy and safety of therapeutic monoclonal antibodies in clinical development and manufacturing.